http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2600891-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6503059ba28fb17a6e9e9652d6a1106d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2011-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e0c3db0c359fcd649f3df573d88d61e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73070e6ac69be7f907d6ce706d1ca341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b3c2b1c5f7063b856f7fd2a80008ffb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58a1aa17e169855e9a088cba65613ab6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b77403b196edbd973be8820087827a9 |
| publicationDate | 2016-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2600891-C2 |
| titleOfInvention | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
| abstract | FIELD: medicine. n SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for detecting the risk of the stage I/II of ovarian carcinoma. To perform it the method includes detection of anti-he4 antibodies in a biological sample obtained from the subject. Meanwhile the presence or amount of anti-he4 antibodies in the biological sample indicates that the subject is at risk of developing of the stage I/II of ovarian carcinoma. Group of inventions also relates to a method of an efficiency control of the treatment of a human with a malignant tumor, receiving the therapeutic treatment for the expressing he4 tumor, and a kit to detect the presence of he4-expressing cells in a subject of individual. Using this group of inventions allows to detect an early stage I/II of ovarian carcinoma by detecting anti-he4 antibodies expression, as well as to provide the control of efficiency of anticancer therapy, where the increase of the level of anti-he4 autoantibodies serves as an indicator of response to the treatment of a patient with the ovarian malignant tumor. n EFFECT: detecting the risk of the stage I/II of ovarian carcinoma. n 24 cl, 4 ex, 2 dwg, 3 tbl |
| priorityDate | 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 585.